These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8588953)

  • 1. Pharmacokinetic, pharmacodynamic, and pharmacotoxic profiles of recombinant-methionyl human interleukin-2[alanine-125] (r-metHuIL-2[ala-125]) following intravenous and subcutaneous administration in rats.
    LeBel CP; Langlois L; Bell DP; Young JD; Kenney WC; Payne BJ; Sendelbach LE; Wong LC
    Hum Exp Toxicol; 1995 Nov; 14(11):909-15. PubMed ID: 8588953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity of subcutaneously administered recombinant human interleukin-2 in rats.
    Wolfgang GH; McCabe RD; Johnson DE
    Toxicol Sci; 1998 Mar; 42(1):57-63. PubMed ID: 9538048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity of human recombinant interleukin-2 in rats. Pathologic changes are characterized by marked lymphocytic and eosinophilic proliferation and multisystem involvement.
    Anderson TD; Hayes TJ
    Lab Invest; 1989 Mar; 60(3):331-46. PubMed ID: 2784516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri).
    Sarmiento UM; Riley JH; Knaack PA; Lipman JM; Becker JM; Gately MK; Chizzonite R; Anderson TD
    Lab Invest; 1994 Dec; 71(6):862-73. PubMed ID: 7807968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ketamine on cocaine-induced immunotoxicity in rats.
    Rofael HZ; Turkall RM; Abdel-Rahman MS
    Int J Toxicol; 2003; 22(5):343-58. PubMed ID: 14555406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats.
    Woo S; Krzyzanski W; Jusko WJ
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1297-306. PubMed ID: 16973883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical safety of recombinant human interleukin-18.
    Herzyk DJ; Bugelski PJ; Hart TK; Wier PJ
    Toxicol Pathol; 2003; 31(5):554-61. PubMed ID: 14692624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial.
    Lubenau H; Bias P; Maly AK; Siegler KE; Mehltretter K
    BioDrugs; 2009; 23(1):43-51. PubMed ID: 19344191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical safety studies with recombinant human interleukin 6 (rhIL-6) in the primate Callithrix jacchus (marmoset): comparison with studies in rats.
    Ryffel B; Weber M
    J Appl Toxicol; 1995; 15(1):19-26. PubMed ID: 7538156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, pharmacokinetics and pharmacodynamics of recombinant human tumour necrosis factor-binding protein-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers.
    Trinchard-Lugan I; Ho-Nguyen Q; Bilham WM; Buraglio M; Ythier A; Munafo A
    Eur Cytokine Netw; 2001; 12(3):391-8. PubMed ID: 11566619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
    Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
    Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration.
    Lieschke GJ; Maher D; O'Connor M; Green M; Sheridan W; Rallings M; Bonnem E; Burgess AW; McGrath K; Fox RM
    Cancer Res; 1990 Feb; 50(3):606-14. PubMed ID: 2404573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone.
    Thygesen P; Andersen HS; Behrens C; Fels JJ; Nørskov-Lauritsen L; Rischel C; Johansen NL
    Growth Horm IGF Res; 2017 Aug; 35():8-16. PubMed ID: 28595133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A four-week repeated study of intravenous toxicity of recombinant human interleukin-2 in Sprague-Dawley rats.
    Lee MJ; Park SH; Kim MJ; Kim HJ; Li Y; Ko KN; Kim D; Lee YH; Kim SH; Jang HS; Baik Y; Lee S; Kang JS; Kang JK
    Regul Toxicol Pharmacol; 2012 Nov; 64(2):253-62. PubMed ID: 22885075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of melphalan on delta-aminolevulinic acid synthetase in the spleen, bone marrow and liver of rats.
    El-Azhary RA; Ahmed AE
    J Pharmacol Exp Ther; 1982 Nov; 223(2):457-61. PubMed ID: 6897078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTP technical report on the toxicity studies of 2-Chloronitrobenzene (CAS No. 88-73-3) and 4-Chloronitrobenzene (CAS No. 100-00-5) Administered by Inhalation to F344/N Rats and B6C3F1 Mice.
    Bucher J
    Toxic Rep Ser; 1993 Jul; 33():1-F25. PubMed ID: 12209191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The lymphatic route. VII. Distribution of recombinant human interleukin-2 in rabbit plasma and lymph.
    Bocci V; Pessina GP; Nicoletti C; Paulesu L
    J Biol Regul Homeost Agents; 1990; 4(1):25-9. PubMed ID: 2399833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTP technical report on the toxicity studies of Riddelliine (CAS No. 23246-96-0) Administered by Gavage to F344 Rats and B6C3F1 Mice.
    Chan P
    Toxic Rep Ser; 1993 Dec; 27():1-D9. PubMed ID: 12209179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic alteration in rats of recombinant interleukin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2.
    Sato J; Hamaguchi N; Doken K; Iwasa S; Ogawa Y; Toguchi H
    Biol Pharm Bull; 1994 Apr; 17(4):535-8. PubMed ID: 8069264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor in the rat. Single and multiple dosing studies.
    Tanaka H; Kaneko T
    Drug Metab Dispos; 1991; 19(1):200-4. PubMed ID: 1708329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.